426 Cases of stage I endometrial carcinoma: A clinicopathological analysis

Marziale, P; Atlante, G; M, Pozzi; Diotallevi, Fabio; Iacovelli, Annunziata

doi:10.1016/0090-8258(89)90624-0

Cited by 18 publications

(5 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As discussed previously by Boronow, not all patients with endometrial cancer are good surgical candidates for extended surgical staging [14]. Marziale et al found that up to 13% of patients with all types of endometrial cancer were not surgical candidates [15]. In the current study, 95.6% of patients who presented with EAE were deemed adequate surgical candidates for extended staging by the attending gynecologic oncologist.…”

Section: Discussionsupporting

confidence: 56%

Pelvic and para‐aortic lymphadenectomy in patients with endometrioid adenocarcinoma of the endometrium

Geisler

Linnemeier

Manahan

2007

Intl J Gynecology & Obste

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 56%

Pelvic and para‐aortic lymphadenectomy in patients with endometrioid adenocarcinoma of the endometrium

Geisler

Linnemeier

Manahan

2007

Intl J Gynecology & Obste

View full text Add to dashboard Cite

show abstract

“…Conventional features do not autleve this aim. In other tumors there is a correlation between DNA content and the clinical course of the disease [9,11,16]. Work on endometrial carcinoma, however, gave different results [5,7,8,14], possibly because of variation in methodology and technology.…”

Section: Discussionmentioning

confidence: 97%

“…Many clinical studies show a favourable prognosis in patients with endometrial carcinoma treated by surgery [9,13]. The nature of surgical treatment and the type of postoperative adjuvant therapy (Tele-Cobalt, hormones) are still subjects for discussions.…”

Section: Discussionmentioning

confidence: 99%

The relation between the results of cytophotometric examination of endometrial carcinoma and clinical course of these disease

Köhler

Taubert

Bilek

et al. 1992

Arch Gynecol Obstet

View full text Add to dashboard Cite

We made a prospective cytophotometric study of 48 cases of endometrial carcinoma. Thirty-two (66.7%) of the cases had diploid DNA content and the proportion of non-diploid tumors increased with the staging of tumors, lack of differentiation and depth of myometrial invasion. DNA content (AE), DNA malignancy grade (DNA-MG) and 5c exceeding rate were statistically significant in relation to the clinical course of the disease and the histological grade of differentiation. DNA parameters appear to be especially suitable for the objective assessment of malignancy.

show abstract

“…Seventeen patients with progressive endometrial adenocarcinoma and a median age of 55 years were treated with GnRH analogues (Table 1). At initial diagnosis eight patients had stage 1 disease but with bad risk prognostic factors (Marziale et al . 1989; Bucy et al .…”

Section: Resultsmentioning

confidence: 99%

A new treatment for endometrial cancer with gonadotrophin releasing‐hormone analogue

Gallagher

Oliver

Oram

et al. 1991

BJOG

View full text Add to dashboard Cite

Objective-To test the antitumour effect of gonadotrophin releasing-hormone (GnRH) analogues in women with recurrent endometrial cancer.Design-An open phase I1 observational trial of GnRH analogues. Serial measurements of gonadotrophins, sex hormones and tumour dimensions were made together with repeat biopsy when possible to assess the response to treatment. Setting-The outpatient clinics of the Department of Medical Oncology at The Royal London, Royal Marsden and St Bartholomew's hospitals. Subjects-17 patients with endometrial cancer which had recurred after surgery, radiotherapy and progesterone treatment and was symptomatic, progressive and assessable for response. Intervention-Monthly subcutaneous injection of GnRH analogue. Main outcome measures-Reduction in serum gonadotrophins and reduction in tumour dimensions. Results-Six out of 17patients (35%, 95% CI 12.6-58%) achieved acomplete or partial remission which continues for a median of 20 months with no adverse effects. Conclurzon-GnRH analogues have a significant antitumour effect in recurrent endometrial cancer which warrants further examination in comparison with progestogens.

show abstract

426 Cases of stage I endometrial carcinoma: A clinicopathological analysis

Cited by 18 publications

References 13 publications

Pelvic and para‐aortic lymphadenectomy in patients with endometrioid adenocarcinoma of the endometrium

Pelvic and para‐aortic lymphadenectomy in patients with endometrioid adenocarcinoma of the endometrium

The relation between the results of cytophotometric examination of endometrial carcinoma and clinical course of these disease

A new treatment for endometrial cancer with gonadotrophin releasing‐hormone analogue

Contact Info

Product

Resources

About